Among the departments—the Public Health Agency, us, CIHR—and also involving the chief science adviser, we're looking overall at strategies to support medical countermeasures, which involves, of course, research, innovation, the industrial response required, biomanufacturing and so on. There is a very interdisciplinary process to bringing in all the different streams of advice that are needed to make critical decisions on what to invest in and what the most promising initiatives are that the government can support.
I'll mention a few examples of the more industrial-scale projects that have been announced. AbCellera is a company in Vancouver that's being supported in working up clinical work on antibody therapy. Also, a company out of Quebec City, Medicago, is working on a vaccine trial but also the technology to scale that up into manufacturing, which needs to be proven out. It's a plant-based approach to scaling up the vaccine, which could hold the promise of being able to achieve scaling in a shorter time period than using some other methodologies that have been used in the past.
Those projects are being reviewed by all the departments and agencies that have equities in the question, to be able to bring to bear the scientific, technical and manufacturing advice needed to make the best possible decisions.